The use of long-acting and topical agents in the treatment of diabetic macular oedema (DMO)
was certainly a key-point at EURETINA 2017, giving plenty of experts a platform to share their opinions. In particular, several groups from all over the world have shared their results and opinions regarding the use of Iluvien ® (fluocinolone acetonide intravitreal implant; Alimera Sciences, Alpharetta, GA, US).
This approach seems fascinating, allowing the patients to achieve much longer treatment-free intervals, and optimal results can be achieved in patients characterised by chronic DMO, corresponding to DMO lasting at least 3 years. Nevertheless, I feel the need to express some concerns about its use, as the incidence of side effects, including cataract and increased intraocular pressure, is higher than other agents even in realworld setting. The identification of biomarkers able to guide the therapeutic choice and to predict the final outcome is of the utmost importance. However, 
